| Autor: |
Jaroonsakchai, Wichaya, Limsrivilai, Julajak, Phaophu, Phutthaphorn, Subdee, Nichcha, Ngamskulrungroj, Popchai, Pausawasdi, Nonthalee, Charatcharoenwitthaya, Phunchai, Pongprasobchai, Supot |
| Předmět: |
|
| Zdroj: |
Siriraj Medical Journal; Apr2024, Vol. 76 Issue 4, p182-188, 7p |
| Abstrakt: |
Objective: Fecal calprotectin (FC) has an essential role in differentiating inflammatory diarrhea from functional diarrhea in an outpatient setting; however, its role in nosocomial diarrhea remains not well explored. Materials and Methods: This is a prospective observational study. We included adult inpatients with nosocomial diarrhea and categorized them into diarrhea likely (group A) and unlikely (group B) to have lesions in the colonic mucosa. Group A included infectious diarrhea such as Clostridium difficile and ischemic colitis. Group B comprised tube-feeding diarrhea, non-C. difficile antibiotic-associated diarrhea, and drug-induced diarrhea. The FC levels were compared between the two groups. Results: 135 patients were included, 45 in group A and 90 in group B. Median FC was 902 mg/kg (interquartile range [IQR] 549-2,175) of feces in group A, significantly higher than the median level of 377 mg/kg (IQR 141-664) of feces in group B (p<0.001). The area under the receiver operating characteristic curve was 0.798 (95% confidence interval: 0.717-0.879). At the standard cutoff of 50 mg/kg of feces, the sensitivity and specificity were 97.8% and 7.8%, respectively. Conclusion: FC was significantly higher in nosocomial diarrhea likely to have mucosal lesions; however, its clinical usefulness was limited due to poor specificity. Trial registration: The trial was registered at ClinicalTrials.gov. (reg. no. NCT04491799. Registered on 26/04/2020). [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
